Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProteoTech has entered into a drug development agreement with GlaxoSmithKline (China) to develop therapies for Parkinson’s disease and other synucleinopathies.
Subscribe to our email newsletter
Both the companies collaborate on ProteoTech’s small molecule technology platform against misfolded proteins to work on its alpha-synuclein therapeutic program.
Michael J. Fox Foundation for Parkinson’s Research has provided funds for over a four-year period to support ProteoTech’s alpha-synuclein therapeutic research program.
ProteoTech CEO Steve Runnels said they are looking forward to work with GlaxoSmithKline on the identification and optimization of new therapeutic compounds for Parkinson’s and other synucleinopathies.